



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(48) Corrigendum issued on:  
**08.06.2022 Bulletin 2022/23**

(45) Date of publication and mention  
of the grant of the patent:  
**02.03.2022 Bulletin 2022/09**

(21) Application number: **15789923.8**

(22) Date of filing: **25.03.2015**

(51) International Patent Classification (IPC):  
**C07D 295/205<sup>(2006.01)</sup> C07D 295/185<sup>(2006.01)</sup>**  
**C07D 295/096<sup>(2006.01)</sup>**

(52) Cooperative Patent Classification (CPC):  
**C07D 295/096; C07D 295/185; C07D 295/205**

(86) International application number:  
**PCT/CN2015/075018**

(87) International publication number:  
**WO 2015/169130 (12.11.2015 Gazette 2015/45)**

(54) **VORTIOXETINE INTERMEDIATE AND SYNTHESIS PROCESS THEREOF**  
VORTIOXETIN-ZWISCHENPRODUKT UND SYNTHESEVERFAHREN DAFÜR  
INTERMÉDIAIRE DE VORTIOXÉTINE ET SON PROCÉDÉ DE SYNTHÈSE

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(30) Priority: **09.05.2014 CN 201410193538**

(43) Date of publication of application:  
**15.03.2017 Bulletin 2017/11**

(73) Proprietors:  
• **Shanghai Syncores Technologies Inc. Ltd.**  
**Shanghai 201203 (CN)**  
• **Zhejiang Huahai Pharmaceutical Co., Ltd**  
**Taizhou, Zhejiang 317024 (CN)**

(72) Inventors:  
• **TANG, Caide**  
**Shanghai 201203 (CN)**  
• **WANG, Gang**  
**Shanghai 201203 (CN)**  
• **WANG, Boyu**  
**Shanghai 201203 (CN)**  
• **HUANG, Luning**  
**Shanghai 201203 (CN)**  
• **GU, Eric**  
**Shanghai 201203 (CN)**

(74) Representative: **Pfenning, Meinig & Partner mbB**  
**Patent- und Rechtsanwälte**  
**Theresienhöhe 11a**  
**80339 München (DE)**

(56) References cited:  
**EP-A1- 0 548 798 EP-A2- 0 957 099**  
**WO-A1-2011/072174 WO-A1-2013/102573**  
**CN-A- 1 541 214**

- **BANG-ANDERSEN, BENNY ET AL.: 'Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl) phenyl] piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder' JOURNAL OF MEDICINAL CHEMISTRY vol. 54, no. 9, 12 April 2011, ISSN 0022-2623 pages 3206 - 3221, XP055058222**
- **ANDERSEN, VALDEMAR L. ET AL.: '11C-labeling and preliminary evaluation of vortioxetine as a PET radioligand' BIOORGANIC & MEDICINAL CHEMISTRY LETTERS vol. 24, no. 11, 19 April 2014, ISSN 0960-894X pages 2408 - 2411, XP028660040**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- BANG-ANDERSEN, BENNY ET AL.: 'Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder' JOURNAL OF MEDICINAL CHEMISTRY vol. 54, no. 9, 12 April 2011, ISSN 0022-2623 pages 3206 - 3221, XP055058222
- KRAFFT, EVA A. ET AL.: 'An improved synthesis of Lu AA20465' TETRAHEDRON LETTERS vol. 47, no. 30, 09 June 2006, ISSN 0040-4039 pages 5355 - 5357, XP025004533
- SEGAWA, J. ET AL.: "Studies on Pyridonecarboxylic Acids. 1. Synthesis and Antibacterial Evaluation of 7-Substituted-6-halo-4-oxo-4H-[1,3]thiazet o[3,2-a]quinoline-3-carboxylic Acids", JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, 1992, pages 4727-4738,